ERA

Download the full-sized PDF of EFFECT OF HYPERLIPIDEMIA  ON DRONEDARONE DISPOSITIONDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3J960Q13

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

EFFECT OF HYPERLIPIDEMIA ON DRONEDARONE DISPOSITION Open Access

Descriptions

Other title
Subject/Keyword
HYPERLIPIDEMIA
DRONEDARONE
DISPOSITION
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
BIN JARDAN, YOUSEF ABDULLAH M
Supervisor and department
DION BROCKS
Examining committee member and department
Ussher, John (Pharmacy and Pharmaceutical Sciences)
El-Kadi, Ayman (Pharmacy and Pharmaceutical Sciences)
Baker, Glen (Psychiatry)
Siraki, Arno (Pharmaceutical Sciences)
Department
Faculty of Pharmacy and Pharmaceutical Sciences
Specialization
Pharmaceutical Sciences
Date accepted
2017-08-04T10:54:50Z
Graduation date
2017-11:Fall 2017
Degree
Doctor of Philosophy
Degree level
Doctoral
Abstract
The pharmacokinetics of dronedarone, effect of hyperlipidemia on dronedarone disposition and dronedarone tissue distribution in normolipidemic (NL) and hyperlipidemic (HL) rats were studied. Novel and sensitive HPLC-UV and LC-MS reverse phase assay methods were developed. Rat plasma (100 μL) was subjected to a one-step liquid-liquid extraction followed by separation of the residues after injection into C18 analytical columns. Both methods had excellent linear relationships between peak height ratios and plasma concentrations. The lower limit of quantification of HPLC-UV (dronedarone and desbutyldronedarone) and LC-MS (dronedarone) based on 100 μL of rat plasma were 25 ng/mL and 5 ng/mL, respectively. The HPLC method was then used to characterize the pharmacokinetic profile of dronedarone in the rat. Single doses were administered to rats intravenously (4 mg/kg), orally (55 mg/kg) and intraperitoneally (65 mg/kg). To induce hyperlipidemia (HL), some of the rats to be given oral dronedarone were administered intraperitoneal doses of poloxamer 407 (P407). Dronedarone was found to possess a high volume of distribution and moderate clearance in the rat. The drug showed poor bioavailability (<20%) after oral and intraperitoneal administration. HL increased dronedarone plasma concentrations measured by area under the plasma concentration vs. time curve. Tissue distribution and hepatic microsomal metabolism experiments were conducted to explore the cause of these changes in HL. After oral single doses of dronedarone, rats were anesthetized and plasma and tissue specimens (heart, lung and liver) were collected. Liver and intestinal microsomal proteins from control, P407 and dietary induced obese rats were harvested and used to measure velocity of desbutyldronedarone (metabolite) formation from dronedarone. HL increased the geometric mean area under the concentration vs. time curves of dronedarone by 2.3 to 5-fold. In tissues (heart, liver and lung), however, concentrations of drug selectively increased or decreased. Heart, the site of action of the drug, had the highest levels of dronedarone. Reductions in liver and intestinal metabolic efficiency (intrinsic clearance) were observed in rats with increased serum lipids (P407 and dietary induced obese) rats compared to controls. The data suggested down regulation in enzymes involved in dronedarone metabolism occurs in the presence of increased lipid levels in the serum, which may explain the higher plasma concentrations in rats given P407.
Language
English
DOI
doi:10.7939/R3J960Q13
Rights
This thesis is made available by the University of Alberta Libraries with permission of the copyright owner solely for the purpose of private, scholarly or scientific research. This thesis, or any portion thereof, may not otherwise be copied or reproduced without the written consent of the copyright owner, except to the extent permitted by Canadian copyright law.
Citation for previous publication
Jardan YA, Gabr RQ, Brocks DR., “Pharmacokinetics of dronedarone in rat using a newly developed high-performance liquid chromatographic assay method”. Biomedical Chromatography. 2014 Aug;28(8):1070-4.Jardan YA, Brocks DR.,” The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats”. Biopharmaceutics Drug Disposition. 2016 Sep;37(6):345-51.

File Details

Date Uploaded
Date Modified
2017-08-04T16:54:50.912+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (PDF/A)
Mime type: application/pdf
File size: 4734985
Last modified: 2017:11:08 17:16:38-07:00
Filename: BIN JARDAN_YOUSEF_AM_201708_PhD.pdf
Original checksum: 1b1cd89d8176eff95cb40aea45d4af04
Activity of users you follow
User Activity Date